Fiche publication
Date publication
avril 2017
Journal
Diabetes & metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel
,
Pr VERGES Bruno
Tous les auteurs :
Petit JM, Vergès B
Lien Pubmed
Résumé
Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.
Mots clés
Fibrosis, GLP-1 receptor agonists, Non-alcoholic fatty liver disease, Steatosis, type 2 diabetes
Référence
Diabetes Metab.. 2017 Apr;43 Suppl 1:2S28-2S33
